A Journal of Postdoctoral Research.
     Login   |   Register   
    ISSN : 2328-9791
left right
Anti-virulence therapy against Pseudomonas aeruginosa: identification of antibiofilm drug
Leoni L, Ungaro F, Imperi F, Fiscarelli EV
University Roma Tre
University Roma Tre, Rome; University of Naples “Federico II”; Sapienza University of Rome; Children’s Hospital “Bambino Gesù”, Rome, Italy 

Background. Early aggressive and maintenance antibiotic therapies prolong cystic fibrosis (CF) patient life, but are not able to eradicate Pseudomonas aeruginosa lung infection. Anti-virulence drugs represent a promising therapeutic option in CF. These drugs could alleviate the severity of the infection, reduce lung inflammation, and help antibiotics in eradicating the P. aeruginosa infection. The long times and high costs required for the development of “brand new” anti-virulence drugs can be saved by repurposing “old” drugs already used in humans for different diseases. We have recently shown that the antimycotic drug flucytosine and the anthelmintic drug niclosamide can be repurposed to suppress P. aeruginosa virulence in vitro and in animal models of infection. However, the old drugs need to be re-formulated for the new application in CF therapy.

Hypothesis and objectives. 1) To develop and validate inhalable formulations of flucytosine and niclosamide for CF therapy. 2) To discovery additional drugs with anti-virulence activity against P. aeruginosa.


home phone mail info@postdocjournal.com
twitter facebook social icon Social link You Tube sky
Click Here